Option Care Health, Inc. Common Stock
OPCH
$31.01
+0.03%
Option Care Health, Inc. is the largest independent provider of home and alternate-site infusion services in the United States, delivering specialty therapies for chronic conditions such as bleeding disorders, neurological disorders, heart failure, and anti-infectives. The company operates a single-segment business model focused on high-touch, cost-effective care outside traditional hospital settings, positioning it as a key player in the shift toward value-based care. The current investor narrative centers on the stock's sharp decline and subsequent partial recovery, driven by concerns over reimbursement pressures, competitive dynamics, and the impact of recent earnings guidance, while management emphasizes long-term growth in the home infusion market. The stock's volatility and the recent analyst activity suggest a period of heightened uncertainty and repositioning as the company navigates a changing healthcare landscape.…
OPCH
Option Care Health, Inc. Common Stock
$31.01
Related headlines
Investment Opinion: Should I buy OPCH Today?
Based on the analysis, OPCH is rated a Buy. The consensus analyst recommendation is Buy with an average target price of $28.58, implying 24.1% upside. The thesis is that the company's dominant position in home infusion services and the expected earnings rebound will drive the stock higher, despite near-term challenges.
Sign up to view all
OPCH 12-Month Price Forecast
The AI assessment is cautiously bullish on OPCH. The stock's forward valuation is compelling, and the analyst consensus supports upside. However, the high debt and thin margins introduce significant risk, and the wide range of analyst targets indicates uncertainty. The stance would be upgraded to strongly bullish if the company delivers a strong earnings beat and raises guidance, while a downgrade to neutral would occur if margins deteriorate or revenue growth stalls. Overall, the risk-reward is favorable at current levels, but investors should monitor execution closely.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Option Care Health, Inc. Common Stock's 12-month outlook, with a consensus price target around $30.68 and implied upside of -1.1% versus the current price.
Average Target
$30.68
0 analysts
Implied Upside
-1.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $39
Analyst target range
Analyst coverage is robust, with 12 analysts covering the stock, and the consensus recommendation is 'Buy' with a mean rating of 2.08 (where 1 is Strong Buy and 5 is Sell). The average target price is $28.58, implying an upside of 24.1% from the current price of $23.03. The distribution of ratings is not provided, but the bullish consensus suggests analysts see value at current levels. The high target of $39.00 implies a 69.3% upside, reflecting expectations of a strong recovery, while the low target of $23.00 is essentially at the current price, indicating some analysts see limited downside. The wide range between low and high targets (16 points) signals high uncertainty about the company's future, likely due to reimbursement and competitive risks. The estimated EPS of $2.76 for the forward period suggests analysts expect a significant earnings rebound, which supports the bullish stance, but the stock's recent volatility and underperformance relative to the market warrant caution.
Drowning in data?
Find the real signal!
Bulls vs Bears: OPCH Investment Factors
OPCH presents a mixed picture: the stock is deeply undervalued on forward earnings (11.1x) and analysts see 24% upside, but the company faces structural headwinds from thin margins, high debt, and reimbursement pressures. The bull case rests on the company's dominant market position and the expected earnings rebound, while the bear case highlights the risk of continued margin compression and competitive disruption. Currently, the evidence slightly favors the bulls given the attractive forward valuation and positive recent momentum, but the key tension is whether the company can achieve the estimated EPS of $2.76, which would require a significant improvement in profitability. If margins fail to expand, the stock could remain range-bound near current levels.
Bullish
- Analyst consensus is Buy with 24% upside: 12 analysts rate OPCH a Buy with a mean recommendation of 2.08 and an average target price of $28.58, implying 24.1% upside from the current $23.03. The high target of $39.00 suggests 69.3% upside if the company executes well.
- Forward P/E of 11.1x is attractive: The forward P/E of 11.14x is significantly lower than the trailing P/E of 24.89x, indicating the market expects substantial earnings growth. With estimated forward EPS of $2.76, the stock trades at a reasonable multiple for a healthcare services leader.
- Revenue growth remains solid: Estimated revenue for the current fiscal year is $7.70 billion, reflecting continued growth in the home infusion market. The company's scale as the largest independent provider positions it to benefit from the shift to value-based care.
- Profitability is positive with improving margins: OPCH is profitable with a net margin of 3.67% and an operating margin of 5.98%. Return on equity is 15.65%, indicating efficient use of shareholder capital, and the company has a current ratio of 1.53, showing adequate liquidity.
Bearish
- Stock is down 21.5% over the past year: OPCH has underperformed the S&P 500 by 41.7 percentage points over the past year, with a 1-year price change of -21.53% versus +20.16% for the index. The stock remains 37.4% below its 52-week high of $36.80.
- High valuation on trailing earnings: The trailing P/E of 24.89x is elevated, and the PEG ratio of 6.12x suggests the stock is expensive relative to its expected growth. This leaves little room for error if earnings disappoint.
- Thin margins and high debt: Gross margin is only 18.06%, and net margin is 3.67%, leaving limited cushion against cost pressures. Debt-to-equity is 0.96, indicating significant leverage that could strain cash flows if interest rates rise.
- Reimbursement and competitive pressures: The home infusion industry faces reimbursement cuts and competition from hospital-based and other alternate-site providers. These pressures could compress margins and slow growth, as reflected in the stock's decline.
OPCH Technical Analysis
Option Care Health's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -21.53%, significantly underperforming the S&P 500's +20.16% gain. The current price of $23.03 sits at 28.6% of its 52-week range (between $18.01 low and $36.80 high), indicating the stock is closer to its lows than its highs, reflecting persistent selling pressure and a lack of sustained buying interest. This positioning suggests the market is pricing in significant headwinds, and the stock remains in a bearish phase despite recent stabilization.
Beta
0.58
0.58x market volatility
Max Drawdown
-46.6%
Largest decline past year
52-Week Range
$18-$37
Price range past year
Annual Return
+14.4%
Cumulative gain past year
| Period | OPCH Return | S&P 500 |
|---|---|---|
| 1m | +28.1% | +0.9% |
| 3m | +43.1% | +3.4% |
| 6m | +6.9% | +14.4% |
| 1y | +14.4% | +16.2% |
| ytd | -3.8% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OPCH Fundamental Analysis
Option Care Health's revenue trajectory has been solid, with estimated revenue of $7.70 billion for the current fiscal year, reflecting a modest growth rate compared to prior periods. The company's gross margin stands at 18.06%, which is relatively low for the healthcare services industry, indicating significant cost of goods sold. Net income is positive, with a net margin of 3.67%, and EPS of $0.04 (likely quarterly), suggesting profitability but with thin margins. The company's operating margin of 5.98% highlights operational efficiency challenges, and the growth rate appears to be decelerating, as evidenced by the stock's price decline and the need to focus on cost management.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OPCH Overvalued?
Given that Option Care Health has positive net income, the primary valuation metric selected is the trailing P/E ratio, which stands at 24.89x. The forward P/E of 11.14x implies a significant earnings growth expectation, as the market anticipates a substantial increase in EPS (estimated at $2.76 for the forward period). The gap between trailing and forward P/E suggests the market expects a major earnings rebound, which may be optimistic given the recent operational challenges. The PEG ratio of 6.12x indicates that the stock is not cheap relative to its expected growth, and the price-to-sales ratio of 0.91x is below the industry average, suggesting the market is not paying a premium for revenue.
PE
24.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for OPCH. The company's gross margin of 18.06% is low, leaving little room for cost increases or pricing pressure, and the net margin of 3.67% means that even small operational hiccups could wipe out profits. Debt-to-equity of 0.96 indicates a high level of leverage, which increases interest expense and financial risk, especially if the company needs to refinance at higher rates. The current ratio of 1.53 is adequate but not robust, and the company's reliance on a single segment (infusion services) concentrates risk in one business line. Additionally, the trailing P/E of 24.89x is high relative to the company's growth rate, suggesting that if earnings do not rebound as expected, the stock could face de-rating.
